RT Journal Article
SR Electronic
T1 Stability of SARS-CoV-2 spike antigens against mutations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.13.22280980
DO 10.1101/2022.10.13.22280980
A1 De la Fuente, Ildefonso M.
A1 Malaina, Iker
A1 Fedetz, Maria
A1 Chruszcz, Maksymilian
A1 Grandes, Gontzal
A1 Targoni, Oleg
A1 Lozano-Pérez, Antonio A.
A1 Shteyer, Eyal
A1 Ya’acov, Ami Ben
A1 de la Cámara, Agustín Gómez
A1 Borobia, Alberto M.
A1 Carrasco-Pujante, Jose
A1 Pijoan, Jose Ignacio
A1 Bringas, Carlos
A1 Pérez-Yarza, Gorka
A1 Ouro, Alberto
A1 Crawford, Michael J.
A1 Shoshan-Barmatz, Varda
A1 Zhurov, Vladimir
A1 López, José I.
A1 Knafo, Shira
A1 Tary-Lehmann, Magdalena
A1 Gabaldón, Toni
A1 Grbic, Miodrag
YR 2022
UL http://medrxiv.org/content/early/2022/10/15/2022.10.13.22280980.abstract
AB Modern health care needs preventive vaccines and therapeutic treatments with stability against pathogen mutations to cope with current and future viral infections. At the beginning of the COVID-19 pandemic, our analytic and predictive tool identified a set of eight short SARS-CoV-2 S-spike protein epitopes that had the potential to persistently avoid mutation. Here a combination of genetic, Systems Biology and protein structure analyses confirm the stability of our identified epitopes against viral mutations. Remarkably, this research spans the whole period of the pandemic, during which 93.9% of the eight peptides remained invariable in the globally predominant 43 circulating variants, including Omicron. Likewise, the selected epitopes are conserved in 97% of all 1,514 known SARS-CoV-2 lineages. Finally, experimental analyses performed with these short peptides showed their specific immunoreactivity. This work opens a new perspective on the design of next-generation vaccines and antibody therapies that will remain reliable against future pathogen mutations.HighlightsOur novel method predicts SARS-CoV-2 epitopes that are stable against future mutationsGenetic analyses (performed 2 years after epitopes were identified) validate the stability of the identified peptidesThese epitopes remained invariable in 97% of all 1,514 known SARS-CoV-2 lineages93.9% of such peptides were conserved in the 43 variants of most interest, including OmicronCompeting Interest StatementThe authors have declared no competing interest.Funding StatementDr. Lozano-Perez acknowledges the European Commission ERDF/FEDER Operational Program 'Murcia' CCI No. 2007ES161PO001 (Project No. 14-20/20). Miodrag Grbic acknowledges support from the NSERC Discovery grant (Canada). This work also has received funding from the Department of Education of the Basque Government via the Consolidated Research Group MATH MODE (IT1456-22). Besides, Ildefonso Martinez De la Fuente and Iker Malaina were supported by the UPV/EHU and Basque Center of Applied Mathematics, grant US21/27.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In Cellular Technology Ltd experiments, all donors provided written informed consent, ethical approval was given by the Institutional Review Board of ADVARRA (Pro00043178). The ELISA assay study was approved and ethical approval given by the Institutional Review Board of ADVARRA. In Shaare Zedek Medical Center (SZMC) the study was approved and ethical approval was given by the Institutional Review Board of Shaare Zedek Medical Center (permit 0181-20-SZMC).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the manuscript or the STAR Methods.